MV Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared on X:
“VIKTORIA-1: ESMO 2026.
Broader blockade. Bigger questions.
Gedatolisib targets pan-PI3K + mTORC1/2, beyond selective PI3Kα inhibition.
- PFS benefit preserved with liver metastases (9.1 vs 4.6 months; HR 0.47).
- ORR: 59% with triplet vs 33% with alpelisib control.
- Safety: Limited glucose impact reported; early stomatitis requires attention.
- TAKE-HOME: Broader pathway inhibition improves PFS, but OS, optimal sequencing and palbociclib’s contribution remain unanswered.
Ref: Pistilli B et al. VIKTORIA-1 Study 2, ESMO 2026. NCT05501886.”
Title: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Authors: Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Sung-Bae Kim, Jorge Luis Martínez Rodríguez, Jorge C. Nadal, Gun Min Kim, Louisa Lo, Yuly A. Remolina-Bonilla, Geronimo Rosselli, George Emile, Ernesto Korbenfeld, Juan Manuel Puig, Robert Wesolowski, Miguel Martin, Alistair Ring, Hyo S. Han, Antonio Giordano, Sarah C. Mutka, Keren Moss, Sam Suzuki, Brian Sullivan, Igor Gorbatchevsky, Barbara Pistilli, VIKTORIA-1 Study Group
You can also read:
